U.S. Markets
Neurocrine confirms it is to acquire Soleno Therapeutics (SLNO) for USD 53/shr in cash or USD 2.9bln
Related stocks
2 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
